| 000 | 07484nam a22004933i 4500 | ||
|---|---|---|---|
| 001 | EBC3019211 | ||
| 003 | MiAaPQ | ||
| 005 | 20240729124115.0 | ||
| 006 | m o d | | ||
| 007 | cr cnu|||||||| | ||
| 008 | 240724s2011 xx o ||||0 eng d | ||
| 020 |
_a9781617613784 _q(electronic bk.) |
||
| 020 | _z9781617611117 | ||
| 035 | _a(MiAaPQ)EBC3019211 | ||
| 035 | _a(Au-PeEL)EBL3019211 | ||
| 035 | _a(CaPaEBR)ebr10663019 | ||
| 035 | _a(OCoLC)847931006 | ||
| 040 |
_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ |
||
| 050 | 4 | _aRC267 -- .H6742 2011eb | |
| 082 | 0 | _a616.994 | |
| 100 | 1 | _aWatanabe, Hiroto S. | |
| 245 | 1 | 0 | _aHorizons in Cancer Research. Volume 42. |
| 250 | _a1st ed. | ||
| 264 | 1 |
_aNew York : _bNova Science Publishers, Incorporated, _c2011. |
|
| 264 | 4 | _c©2011. | |
| 300 | _a1 online resource (236 pages) | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 490 | 1 | _aHorizons in Cancer Research Series | |
| 505 | 0 | _aIntro -- HORIZONS IN CANCER RESEARCH. VOLUME 42 -- HORIZONS IN CANCER RESEARCH. VOLUME 42 -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I Signaling Pathways as Biomarkers in Human Renal Cell Carcinoma -- Summary -- Introduction -- Notch Signaling Pathway -- P53 Signaling Pathway -- HIF Signaling Pathway -- VEGF/R Signaling Pathway -- EGFR Signaling Pathway -- Carbonic Anhydrase 9 -- Fumarate Hydratase -- GLUT Transporters -- Crosstalk between Notch Pathway and HIF Signaling -- Crosstalk between Notch Pathway and EGFR Signaling -- Crosstalk between Notch Pathway and VEGF Signaling -- Crosstalk of Notch Pathway with P53 Signaling -- Conclusion -- Acknowledgments -- References -- Chapter II Role of Prostate-Specific Antigen (PSA) in Pathological Angiogenesis and Prostate Tumor Growth -- Abstract -- Conclusion -- Acknowledgments -- References -- Chapter III Elapsed Times in the Management of Early Stage Breast Cancer -- Abstract -- Introduction -- Do longer elapsed times impact breast cancer outcomes? -- Detection to Treatment -- Detection to Diagnosis -- Detection to Surgery -- Surgery to Chemotherapy -- Surgery to Radiotherapy -- Summary & -- Caveats -- What are the predictors of longer elapsed times in Canada? -- Detection to Diagnosis -- Detection to Surgery -- Surgery to Chemotherapy -- Surgery to Radiotherapy -- Summary & -- Caveats -- A multi-interval multi-resolution analytics framework -- Conclusions -- Acknowledgments -- References -- Chapter IV Positional Cloning of Tumor Suppressor Genes from 3p21.3 Involved in Major Human Cancers -- 1. Abstract -- 2. Introduction -- 3. Results -- a) Localization of Critical Regions on the Short Arm of Chromosome 3 Using Allelotyping of the Dense Set of Polymorphic Markers. | |
| 505 | 8 | _aMultiple interstitial deletions were found in prevalence to terminal deletions in 3p in five epithelial tumor types -- Chromosome 3p "hot spots" affected in major epithelial tumors -- Contribution of amplification events in allelic alterations of 3p microsatellites -- Correlation of 3p allelic alterations with tumor progression -- b) Careful Mapping of LUCA and AP20 Regions Using Real Time Quantitative PCR -- QPCR for detection copy number changes -- QPCR results for RCC, BC and SCLC tumor samples and cell lines -- Comparison of LOH and QPCR data. fine deletion mapping of homozygous deletions -- Complex 3p rearrangements in major epithelial cancers -- c) NotI-Microarrays to Identify Cancer Causing Genes and Develop Biomarkers for Early Diagnosis, Prognosis and Prediction of Major Types of Cancer -- d) Identification of Novel Tumor Suppressor Genes -- Conclusion -- Acknowledgments -- References -- Chapter V Novel Methylation-Dependent Markers/Tumor Suppressor Genes Involved in the Development of Renal Cell Cancer -- Abstract -- Introduction -- RCC Methylation Profiles of RASSF1A, SEMA3B, RARbeta2, RHOA, GPX1, USP4 Genes -- Genes in the LUCA Critical Region (3p21.31) -- Genes in a Novel 3p21.3 MECA3 Region (3р21.31) -- Genes from the Distal 3p Region (3p26-P22) -- RCC Specific Methylation Profile for Six 3p Genes -- Methylation Pattern of RASSF1A, RAR-Beta2, SEMA3B, GPX1 and Tumor Progression -- Expression Profiles of Cancer Associated Genes: RBSP3, SEMA3B, SEMA3F, NPRL2, HYAL1, HYAL2, ITGA9, VILL, CHL1, and ACY1 in RCC -- High Mutation Frequency of the Tumor Suppressors RASSF1 and RBSP3 (CTDSPL) in RCC -- NotI Microarrays for Identification of RCC Biomarkers -- Conclusion -- Acknowledgments -- References -- Chapter VI Human Papillomaviruses (HPVs), Genomic Instability and the DNA Damage Response -- Abstract -- Human Papillomaviruses and Cancer. | |
| 505 | 8 | _aThe Role of HPV Oncoproteins in the Viral Life Cycle -- Disruption of G1/S-Cell Cycle Checkpoint Regulation by High-Risk HPV Oncoproteins -- The Role of High-Risk HPV Oncoproteins in Genomic Instability and Cancer -- The Cellular DNA Damage Response -- DNA Damage -- ATM and ATR DNA Damage Checkpoint Kinases -- Downstream Targets of ATM and ATR -- The Fanconi Anemia (FA) Pathway -- DNA Repair Mechanisms -- High-Risk HPV Oncoproteins and the DNA Damage Response -- High-Risk HPV Oncoproteins Stimulate DNA Damage -- High-Risk HPV E7 Expression Triggers a Host Cell DNA Damage Checkpoint Response -- Interactions between High-Risk HPV Oncoproteins and the DNA Damage Response Machinery -- How Does the High-Risk HPV E7 Oncoprotein Induce DNA Damage and DNA Damage Checkpoint Activation? -- Advantages and Disadvantages of Interference with the Host Cell DNA Damage Response by HPV Oncoproteins -- Exploitation of the DNA Damage Response and the Viral Life Cycle -- Abrogation of the DNA Damage Response -- Future Directions -- Acknowledgments -- References -- Chapter VII Prophylactic Cranial Irradiation in Non-Small Cell Lung Cancer -- Abstract -- Introduction -- Factors Associated with Brain Metastases -- 1. Chemotherapy -- 2. Stage -- 3. Histology and Age -- Treatment of Brain Metastases -- PCI in Patients with NSCLC (Table 2) -- 1. Nonrandomized Study of PCI -- 2. Randomized Stuies of PCI -- Toxicity of PCI -- PCI: When and How? -- Conclusion -- References -- Chapter VIII Importance of Cell Cycle Regulatory Proteins and Proliferation Markers in Conventional Renal Cell Carcinoma -- Abstract -- Introduction -- Methods -- Results -- Conclusion -- Introduction -- Materials and Methods -- Patient Groups -- Tissue Sampling and Immunohistochemistry -- Sample Scoring and Statistical Analysis -- Results -- Conclusion -- References. | |
| 505 | 8 | _aChapter IX Overview of Kidney Cancer: Symptoms, Diagnosis, and Treatments -- Signs and Symptoms -- Diagnosis -- Treatments -- References -- Index. | |
| 588 | _aDescription based on publisher supplied metadata and other sources. | ||
| 590 | _aElectronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
| 650 | 0 | _aCancer -- Research. | |
| 650 | 0 | _aCancer -- Treatment. | |
| 655 | 4 | _aElectronic books. | |
| 776 | 0 | 8 |
_iPrint version: _aWatanabe, Hiroto S. _tHorizons in Cancer Research. Volume 42 _dNew York : Nova Science Publishers, Incorporated,c2011 _z9781617611117 |
| 797 | 2 | _aProQuest (Firm) | |
| 830 | 0 | _aHorizons in Cancer Research Series | |
| 856 | 4 | 0 |
_uhttps://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3019211 _zClick to View |
| 999 |
_c60127 _d60127 |
||